Gapping up
In reaction to strong earnings/guidance:
- EDU +3.8%, LOGI +2.6%, ONB +1.2%, STLD +1%
Other news:
- MDWD +26.7% (announces that it has met its primary and all secondary endpoints in its pivotal U.S. Phase 3 clinical study)
- TGTX +19% (granted Breakthrough Therapy Designation for umbralisib from the FDA)
- SRNE +13% (announces interim results in osteoarthritis knee pain Phase 1b trial)
- NOG +4.6% (provides Q4 business update)
- EYPT +4.4% (entered into $20 mln At Market Issuance Sales Agreement)
- CYTK +4.2% (announces receipt of FDA feedback regarding reldesemtiv in patients with SMA -- six minute walk test acceptable as primary efficacy endpoint for potential registration program)
- EXK +2.6% (provides FY18 mineral reserve and resource estimates)
- TLRY +2% (will acquire all of the issued and outstanding securities of Natura Naturals Holdings for CAD 35 mln in cash and stoc)
- NNBR +1.7% (Legion partners discloses increased holding -- with 6.35% active stake)
- GOLD +1.6% (reports preliminary Q4 production results)
- TSLA +1.1% (modestly rebounding)
- LIN +0.8% (authorized a share repurchase program for up to $6.0 billion of its ordinary shares)
Analyst comments:
- UAA +4.4% (added to Conviction Buy List at Goldman)
- DRNA +2.1% (upgraded to Buy at Chardan Capital Markets)
- PANW +1.8% (upgraded to Buy from Neutral at UBS; upgraded to Outperformat BMO Capital Markets)
- CARS +0.9% (upgraded to Buy from Neutral at BTIG Research)
- NKE +0.9% (upgraded to Outperform from Market Perform at Cowen)